Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| CooperVision and CooperSurgical both posted strong results, and we expect this to continue |
| We're off to an outstanding start this year, posting all-time record quarterly revenues of $932 million |
| CooperVision started the year on a solid note, growing nicely around the world and CooperSurgical achieved record quarterly revenues with our fertility business posting its 13 consecutive quarter of double-digit organic growth |
| Our earnings were strong and our momentum is excellent with capacity expansion progressing well and demand remaining very healthy |
| We're in a really good position moving forward |
| CooperVision posted revenues of $622 million, up 7%, led by strength in our daily silicone hydrogel portfolio |
| And CooperSurgical posted revenues of $310 million, up 8%, led by another great quarter in our fertility business |
| Margins improved, and profits were solid with non-GAAP earnings per share of $0.85, remembering that we just completed a 4-for-1 stock split last week |
| So yes, you picked up on that is a good point because that is a benefit, and it's going to help us continue to drive growth |
| All three regions reported success with our innovative product portfolios, market-leading flexibility and growth in key accounts |
| And our marketing team has done a really nice job there and the development team on streamlining some of that activity to ensure that optometrists understand the fitting process and are able to do it very quickly |
| We're continuing to see outsized demand, especially for MyDay, where our capacity is improving, and this is reflected in our higher revenue guidance that we'll cover shortly |
| We're seeing very strong growth in demand with MyDay |
| Starting with MyDay multifocal, our momentum is truly fantastic |
| And that would be a really exciting thing and really open the doors to a pretty significant market for us |
| But I would probably say, yes, MiSight really strong, maintaining strong |
| That's being driven by underlying strength in those key accounts, whereas you know, Jason, right, we have a good relationship with a lot of them through the store brands and so forth right now |
| I'm comfortable saying these are the best multifocals in the market and our outstanding growth and strong demand certainly supports that |
| This lens is also performing extremely well |
| The rollout of our parameter expansion across North America and Europe has been a tremendous success, and we look forward to increasing availability as capacity improves |
| It's just solid, consistent progress, right? That's why we did, what, 50%, a little over 50% growth this quarter |
| market and is continuing to generate great results |
| The other place that you'll see strong numbers, we're doing well from a fit perspective is in the daily silicone hydrogel side of things |
| Meanwhile, our premium MyDay sphere is also posting great results |
| To wrap up on MyDay, our team has done a phenomenal job supplying existing customers while keeping expectations in check on new product launches and geographic expansion |
| I'm now happy to report that our success expanding capacity is easing some of those constraints and allowing us to be more active moving forward |
| With its full family of silicone hydrogel spheres, torics and multifocals, we're continuing to do well |
| We have a great position in those categories and leadership position, right? We do really well |
| But I'm comfortable continuing to say that our fit data is in excess of our market share, which is a really good sign for us |
| It's worth highlighting our Biofinity toric multifocal, which is growing very nicely as eye care practitioners continue making it their primary lens for patients experiencing more complex vision needs balancing presbyopia with differing levels of astigmatism |
| Statement |
|---|
| Outside of MiSight, our Ortho K lenses declined 10% due to weakness in China |
| It's a loss, as you can imagine right now, as we continue to invest in it |
| If you look at legacy hydrogels and some of that kind of stuff, right, there's -- we certainly have weakness in those areas |
| So when you look at allocation of product and capacity constraints that we had, that negatively impacted Asia Pac and probably will, frankly, a little bit again here in the second quarter |
| The underlying demand is still a struggle there in terms of being able to grow volumes |
| Certainly, Q2 and Q3 are worse from an operating profit or a gross profit perspective |
| Below operating income, interest expense was $28.6 million, and the effective tax rate was lower than expected at 13.3% due to stock option exercises |
| It was down quarter-over-quarter |
| Outside of the FX piece, which is negative to us on revenues and EPS and some OI, frankly, and cost of goods, we're still holding gross margins pretty similar to last year |
| Not too much to say on that other than I think it got picked up a little bit about some communication we had in Japan with respect to some capacity constraints |
| So this is an issue that impacts a lot of people and will continue to do so in the future |
| The impact from FX was $0.03 negative year-over-year for the quarter |
| And the full year impact is still roughly a negative 1% to revenues and a negative 5% to earnings |
| And from a gating perspective, I wouldn't really point out anything in particular outside of the fact that FX, as we've been telling people last quarter, is a bit more of a negative in Q2, which is our worst FX quarter, and so it's going to impact us a little bit there |
| Now that's largely a U.S.-based thing because it's side to Alabama in the court like, we were like -- I won't kind of get in my high horse, if you will, of my frustration about what's going on there |
| But if that does get approved and hit the market, that would impact us |
| So it's tough |
| But as we look at next year and the years thereafter, I would expect it to come down on a percentage basis |
| One of the challenges that optometrists have with MiSight is they bring the child in |
| But we are seeing some volatility with respect to the Ortho K market and certainly within China |
Please consider a small donation if you think this website provides you with relevant information